ライフサイエンスコーパス: Janus kinase 2

1 nase), JNK (Jun N-terminal kinase), or JAK2 (Janus kinase 2).

2 on via a specific interaction with activated Janus kinase 2.

3 n and downstream signaling through activated Janus kinase 2.

4 ic kidney 293T cells that express endogenous Janus kinase 2.

5 s could be reversed by administration of the Janus kinase 2/3 inhibitor tofacitinib, which blocks IL-

6 cyclin-dependent kinase inhibitor), AT9283, (Janus kinase 2/3 inhibitor), ispinesib (kinesin spindle

7 ating mutation (V617F) in the gene for JAK2 (Janus kinase 2), a tyrosine kinase utilized by hematopoi

8 Phase I clinical testing of inhibition of Janus kinase 2, active in vitro, began with several agen

9 tion of the redox-sensitive protein kinases (Janus kinase 2, Akt, and p38 mitogen-activated protein k

10 The high prevalence of the V617F mutation of Janus kinase 2 and associated mutations in myeloprolifer

11 rms of the relationship between dysregulated Janus kinase 2 and elevated blood counts.

12 r (MPL) to induce constitutive activation of Janus kinase 2 and signal transducer and activator of tr

13 support Epo-dependent cell growth or trigger Janus kinase 2 and STAT5 activation, even at concentrati

14 However, only IL-3 and IL-5 induced Janus kinase 2 and STAT5 phosphorylation.

15 ompounds are designed to bind selectively to Janus kinase 2 and the STAT3 Src homology-2 domain, whic

16 zed the response of bone to GH by increasing Janus kinase-2 and IGF-1R protein levels.

17 The V617F activating mutation of Janus kinase 2, and associated parallel mutations, is at

18 We found that IL-3-induced Janus kinase 2-dependent expression of SLC7A5 and SLC3A2

19 gulation of HMGB1 release through a TNF- and Janus kinase 2-dependent mechanism.

20 notypic consequence of the V617F mutation in Janus kinase 2 (encoded by JAK2), but the extent to whic

21 proliferation and constitutive activation of Janus kinase 2, ERK1, and ERK2.

22 ntly identified gain-of-function mutation in Janus kinase 2, found in the majority of patients with m

23 sis carry a gain-of-function mutation in the Janus kinase 2 gene (JAK2 V617F) that contributes to the

24 Somatic mutations in the Janus kinase 2 gene (JAK2) occur in many myeloproliferat

25 rimary myelofibrosis carry a mutation in the Janus kinase 2 gene (JAK2), and an additional 5 to 10% h

26 also mimicked apolipoproteins in activating Janus kinase 2; however, the M159D/E mutants were also a

27 s up-regulated by PHx through a GH-mediated, Janus kinase 2-independent, SRC family kinase-dependent

28 123319 (AT(2) inhibitor), AG 490 (a specific Janus kinase 2 inhibitor), and genistein (a tyrosine kin

29 Compared with AG490, a well-characterized Janus kinase 2 inhibitor, curcumin was a more rapid (30

30 JAK2 (Janus kinase 2) is essential for cytokine receptor signa

31 , up-regulates heparanase expression via the Janus kinase 2 (JAK-2) pathway.

32 soluble IL-6 receptor (IL-6R) and stimulated Janus kinase-2 (JAK) and signal transducer and activator

33 y tyrosine phosphorylation and activation of Janus kinase-2 (Jak-2), Tyk-2, Stat3, and Stat4.

34 point mutation in the pseudokinase domain of Janus kinase 2 (JAK2 V617F).

35 uired gain-of-function V617F mutation in the Janus Kinase 2 (JAK2(V617F)) is the main mutation involv

36 etic deletion in the hematopoietic system of Janus kinase 2 (JAK2) abrogates initiation of myeloproli

37 Epo addition, the EpoR signaling through the Janus kinase 2 (JAK2) activates multiple pathways includ

38 es L253, I257, and W258, that is crucial for Janus kinase 2 (JAK2) activation and receptor signaling.

39 Using the chemical inhibitor of Janus kinase 2 (Jak2) activity, AG 490, and overexpressi

40 G also activates the growth-promoting enzyme janus kinase 2 (JAK2) and its latent signal transducers

41 channels in LH neurons via the activation of janus kinase 2 (JAK2) and of mitogen-activated protein k

42 an stimulate the tyrosine phosphorylation of Janus kinase 2 (JAK2) and other members of the JAK/signa

43 This leads to the activation of Janus kinase 2 (JAK2) and phosphorylation of signal tran

44 prevented the decrease of phosphorylation of Janus kinase 2 (JAK2) and phosphorylation of signal tran

45 nhibits interferon-gamma (IFN-gamma)-induced Janus kinase 2 (JAK2) and signal transducer and activati

46 sulting in a loss of downstream signaling by Janus kinase 2 (JAK2) and signal transducer and activato

47 GH triggered the tyrosine phosphorylation of Janus kinase 2 (Jak2) and STAT3 in neutrophils.

48 crovascular endothelial cell line-1 (HMEC-1) Janus kinase 2 (JAK2) and that the JAK2 inhibitor, AG-49

49 ndocytic AMR controls TPO expression through Janus kinase 2 (JAK2) and the acute phase response signa

50 he prolactin receptor (PRLR), its associated Janus kinase 2 (Jak2) and the signal transducer and acti

51 Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for th

52 dermal growth factor receptor (EGFR) utilize Janus kinase 2 (JAK2) as a common signaling node to tran

53 Here, we investigated the role of Janus kinase 2 (JAK2) as a newly described intracellular

54 Inhibitors of Ca(2+)/calmodulin (CaM) and Janus kinase 2 (Jak2) attenuated this activation, wherea

55 The tyrosine kinase Janus kinase 2 (JAK2) binds to the majority of the known

56 The cytoplasmic tyrosine kinases Src and Janus kinase 2 (Jak2) both seem to be involved in the ac

57 Activation of Janus kinase 2 (JAK2) by chromosomal translocations or p

58 s study, we show that the hyperactivation of Janus kinase 2 (JAK2) by the V617F mutation phosphorylat

59 e receptor-like factor 2 (CRLF2) and mutated Janus kinase 2 (Jak2) cooperated in conferring cytokine-

60 imerization and revealed that the associated Janus kinase 2 (JAK2) dimerizes through its pseudokinase

61 Cytokines, which utilize Janus kinase 2 (Jak2) for signaling, drive the inflammat

62 s in the bone marrow due to mutations in the Janus kinase 2 (JAK2) gene.

63 Janus kinase 2 (JAK2) has been linked to various neutrop

64 Tyr(1007) residue in the activation loop of Janus kinase 2 (JAK2) has been shown to be essential for

65 The nonreceptor kinase Janus kinase 2 (JAK2) has garnered attention as a promis

66 ortant axis in memory CD8(+) T cells couples Janus kinase 2 (JAK2) hyperactivation to the phosphoryla

67 to phosphatidylinositol 3-kinase and Akt via Janus kinase 2 (JAK2) in a cascade, which results in neu

68 s) is the acquisition of a V617F mutation in Janus kinase 2 (JAK2) in hematopoietic stem cells (HSCs)

69 ine kinase (IRTK) and leptin receptor (LEPR)-Janus kinase 2 (JAK2) in hypothalamic nuclei.

70 cotine activates the growth-promoting enzyme Janus kinase 2 (JAK2) in PC12 cells and that preincubati

71 ETE also induced tyrosine phosphorylation of Janus kinase 2 (Jak2) in VSMCs, and its inhibition subst

72 significantly blocked by the highly specific janus kinase 2 (JAK2) inhibitor alpha-cyano-(3,4-dihydro

73 s are used for first-line treatment, and the Janus kinase 2 (JAK2) inhibitor ruxolitinib is second-li

74 tive to TG101348, a selective small-molecule Janus kinase 2 (JAK2) inhibitor.

75 ncreatic tumors were given gemcitabine and a Janus kinase 2 (JAK2) inhibitor; tumor growth was monito

76 Developing Janus kinase 2 (Jak2) inhibitors has become a significan

77 modifying agents (CMAs) but not hydroxyurea, Janus kinase 2 (JAK2) inhibitors, or low doses of interf

78 Janus kinase 2 (JAK2) is a central kinase in hematopoiet

79 inflammation underlies atherosclerosis, and Janus kinase 2 (Jak2) is a critical signaling node that

80 The discovery that aberrant activity of Janus kinase 2 (JAK2) is a driver of myeloproliferative

81 The V617F mutation in the JH2 domain of Janus kinase 2 (JAK2) is an oncogenic driver in several

82 Janus kinase 2 (JAK2) is associated with LEPRb and autop

83 quired for adequate basal signaling, whereas Janus kinase 2 (JAK2) is dispensable upstream of STAT3.

84 The Janus kinase 2 (Jak2) is essential for normal mammary gl

85 We recently found that activation of janus kinase 2 (JAK2) is essential for the Ang II-induce

86 The redox regulation of Janus kinase 2 (JAK2) is poorly understood, and there ar

87 ed to assess the effects of NADPH oxidase on Janus kinase 2 (JAK2) kinase, the low molecular weight-p

88 p24.1 amplification region also included the Janus kinase 2 (JAK2) locus.

89 e show that the protein-tyrosine kinase (TK) Janus kinase 2 (JAK2) modulates the apolipoprotein inter

90 "TET2-first patients"), patients in whom the Janus kinase 2 (JAK2) mutation was acquired first ("JAK2

91 Janus kinase 2 (JAK2) mutations define polycythemia vera

92 Second, when Janus kinase 2 (Jak2) phosphorylation was inhibited usin

93 Janus kinase 2 (JAK2) plays a critical role in orchestra

94 eedforward loop in which p27pT157pT198 binds Janus kinase 2 (JAK2) promoting STAT3 (signal transducer

95 Expression of Janus kinase 2 (JAK2) R867Q and S755R/R938Q induced spon

96 Janus kinase 2 (JAK2) signaling is increased in human an

97 is controlled by cytokine receptor-mediated Janus kinase 2 (JAK2) signaling.

98 We recently developed a Janus kinase 2 (Jak2) small molecule inhibitor called G6

99 Activating alleles of Janus kinase 2 (JAK2) such as JAK2(V617F) are central to

100 The tyrosine kinase Janus kinase 2 (JAK2) transduces signaling for the major

101 matic activating mutation (JAK2V617F) in the Janus kinase 2 (JAK2) tyrosine kinase in the myeloprolif

102 on of the phosphoinositol 3-kinase (PI3K) or Janus kinase 2 (Jak2) tyrosine kinase inhibitors abolish

103 tion in the JH2 autoinhibitory domain of the Janus kinase 2 (JAK2) tyrosine kinase was recently descr

104 iates signaling by activating the associated Janus kinase 2 (Jak2) tyrosine kinase, which promotes th

105 The Janus kinase 2 (JAK2) V617F mutation is the primary path

106 ostate cancer, a dominant-negative mutant of Janus kinase 2 (Jak2) was delivered by adenovirus to CWR

107 combined targeting of the BCR-ABL kinase and Janus kinase 2 (JAK2) with dasatinib and ruxolitinib, re

108 AG-490, a selective inhibitor of Janus kinase 2 (Jak2), also reduced the LPC-induced Sp1

109 After cotransfection of Ob-Rb, Janus kinase 2 (JAK2), and SHP-2 into 293T cells, leptin

110 8 inhibits tyrosyl phosphorylation of STAT3, Janus kinase 2 (JAK2), and Src.

111 anism that is dependent upon beta1 integrin, Janus kinase 2 (JAK2), and STAT3 but not EGFR.

112 Phosphorylated STAT3, phosphorylated Janus kinase 2 (JAK2), and suppressor of cytokine signal

113 growth factor beta receptor (PDGFbetaR), TEL/Janus kinase 2 (JAK2), and TEL/neurotrophin-3 receptor (

114 enerated by NADPH oxidase, the activation of Janus kinase 2 (JAK2), and the polyol pathway play impor

115 phospholipase C, Ca2+/calmodulin (CaM), and Janus kinase 2 (Jak2), but not by pertussis toxin or by

116 and are characterized by mutually exclusive Janus kinase 2 (JAK2), calreticulin (CALR), and myelopro

117 receptor-associated Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2), concurrent with deletion of the w

118 Pacritinib (SB1518) is a Janus kinase 2 (JAK2), JAK2(V617F), and Fms-like tyrosin

119 (Akt1), Ras homolog enriched in brain (Rheb) Janus kinase 2 (Jak2), or signal transducer and activato

120 s did not affect tyrosine phosphorylation of Janus kinase 2 (JAK2), Shc, signal transducer and activa

121 (-/-) mice did not affect phosphorylation of Janus kinase 2 (JAK2), signal transducer and activator o

122 enhanced H(2)O(2)-induced phosphorylation of Janus kinase 2 (JAK2), signal transducer and activator o

123 l and activates signaling molecules, such as Janus kinase 2 (JAK2), that optimize the lipid export ac

124 elated Receptor Tyrosine Kinase 3 (FLT3) and Janus Kinase 2 (JAK2), was further studied.

125 tracytoplasmic tyrosine kinases, essentially janus kinase 2 (JAK2), which regulates MPL stability and

126 culin (CALR) mutations have been reported in Janus kinase 2 (JAK2)- and myeloproliferative leukemia (

127 quires p53, we find that irinotecan inhibits Janus kinase 2 (JAK2)-signal transducer and activator of

128 red the human PRL-prolactin receptor (hPRLR)-Janus kinase 2 (JAK2)-signal transducer and activator of

129 PI3K-PDE3B-cAMP pathway interacting with the Janus kinase 2 (Jak2)-Stat3 pathway constitutes a critic

130 we demonstrated that inhibition of the IL-6-Janus kinase 2 (JAK2)-STAT3-calprotectin axis with FDA-a

131 uences of Stat1 deficiency on the effects of Janus kinase 2 (JAK2)-V617F in vivo by crossing mice exp

132 CIPs), and presence of the V617F mutation in Janus kinase 2 (JAK2).

133 nonreceptor protein tyrosine kinases Lyn and janus kinase 2 (Jak2).

134 uperfamily members that bind to and activate Janus kinase 2 (JAK2).

135 (PI(4,5)P(2)) and the FERM-SH2 domain of the Janus kinase 2 (JAK2).

136 sential thrombocythemia (ET) with nonmutated Janus kinase 2 (JAK2).

137 cathepsin K(+) OCs expressing phosphorylated Janus kinase 2 (JAK2).

138 short-interfering RNA-mediated knockdown of Janus kinase 2 (JAK2).

139 ting mutations of signaling proteins such as Janus kinase 2 (JAK2).

140 ffects are mediated by the activation of the Janus kinase 2 (Jak2)/signal transducer and activator of

141 C, which promoted the activation of the IL-6/Janus kinase 2 (JAK2)/signal transducer and activator of

142 Blockade of HGF/Met, Janus kinase 2 (JAK2)/STAT3 and TGF-beta1 signaling by s

143 ulated by retinoic acid 6" (STRA6), enhanced Janus kinase 2 (JAK2)/STAT5 cascade, up-regulated adenyl

144 The inclusion of a transgenic allele of Janus kinase 2 (JAK2)V617F resulted in acceleration of t

145 ranscription 5) signaling pathway, including Janus kinase 2 (JAK2, 64%), calreticulin (CALR, 23%), an

146 ross-talk between the signalling pathways of Janus kinase-2 (Jak2) and nuclear factor-kappaB (NF-kapp

147 various protein tyrosine kinases, including Janus kinase-2 (Jak2) and the insulin receptor.

148 Janus kinase-2 (JAK2) conveys receptor-binding signals b

149 The critical role of Janus kinase-2 (JAK2) in regulation of myelopoiesis was

150 Mutations in Janus kinase-2 (JAK2) occur in approximately 50% of pati

151 The tyrosine kinase, Janus kinase-2 (Jak2), plays a pivotal role in signal tr

152 receptor-associated protein tyrosine kinase janus-kinase 2 (JAK2) is essential for normal red cell d

153 ctor receptor [EGFr] inhibitor) and AG490 (a Janus kinase 2 [JAK2] inhibitor), SB203580 (a p38 inhibi

154 and downstream effectors of IL-13 signaling (Janus kinase-2 [JAK2] and signal transducer and activato

155 patients have a gain of function mutation in Janus kinase 2 (JAK2V617F), but little is known how JAK2

156 the epidermal growth factor receptor kinase, Janus kinase-2 kinase, and Src kinase did not block the

157 Mice with hepatocyte-specific deletion of Janus kinase 2 (L-JAK2 KO mice) develop spontaneous stea

158 S1 interaction with Toll-like receptor-4 and Janus kinase-2 leading to impairment of SOCS1 inhibitory

159 The Janus kinase 2 mutation, JAK2617V>F, is myeloid neoplasm

160 AG490, a specific inhibitor for Janus kinase 2 of the IFN-gamma signaling pathway, dose-

161 lipopeptide did not affect the activation of Janus kinase 2 or its association with beta c.

162 Inhibition of Janus kinase 2 or SRC kinase signaling downstream of mut

163 x O1, extracellular signal-regulated kinase, Janus kinase 2, or signal transducers and activators of

164 d this required intact signaling through the Janus Kinase 2/phosphatidylinositol-4,5-bisphosphate 3-k

165 In addition, the rate of Janus kinase 2 phosphorylation, initiated through the th

166 a selective inhibitor of Janus kinase 1 and Janus kinase 2, potently suppresses cytokine signaling i

167 tes the formation of a complex with IRS2 and Janus kinase 2, preventing IRS2 ubiquitination.

168 he phosphorylation of Lyn, the Epo receptor, Janus kinase 2, Signal Transducer and Action of Transcri

169 teins included constitutively phosphorylated Janus kinase 2, signal transducer and activator of trans

170 The cardiac Janus kinase 2-Signal Transducer and Activator of Transc

171 d PD-L2, and their further induction through Janus kinase 2-signal transducers and activators of tran

172 tokine receptor superfamily that signals via Janus kinase-2-signal transducer and activator of transc

173 cyclin D1 through phosphoinositide 3-kinase, Janus kinase 2/signal transducer and activator of transc

174 oid progenitors EPOR engagement of canonical Janus kinase 2/signal transducer and activator of transc

175 ssion is mediated, at least in part, via the Janus kinase 2/signal transducers and activators of tran

176 The Janus kinase 2/signal transducers and activators of tran

177 R (Ghr(-/-) ), disabled for all GH-dependent Janus kinase 2 signaling (Box1(-/-) ), or lacking only G

178 aB pathway, however, IL-12 signaling through Janus kinase 2/Stat4 activation was markedly suppressed.

179 osine phosphorylation, and activation of the Janus kinase 2, STAT5, extracellular signal-regulated ki

180 ere, we hypothesized that APC-specific JAK2 (Janus kinase 2) through STAT3 (signal transducer and act

181 An activating 1849G>T mutation of JAK2 (Janus kinase 2) tyrosine kinase was recently described i

182 ed IL-12-induced tyrosine phosphorylation of Janus kinase 2, tyrosine kinase 2, and STAT3 and STAT4 t

183 from polycythemia vera patients harboring a Janus kinase 2 V617F mutation in hematopoietic stem cell

184 ythropoietin (EPO), its receptor (EPOR), and janus kinase 2 were cloned; established to be essential